Get startedLog in
    Picture of Dawnrays Pharmaceutical (Holdings) logo

    2348 — Dawnrays Pharmaceutical (Holdings) Income Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareConservativeSmall CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Dawnrays Pharmaceutical (Holdings), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    HKAS
    HKAS
    HKAS
    HKAS
    HKAS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue1,1651,2781,1511,0601,231
    Cost of Revenue
    Gross Profit675767628532557
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses679777695416981
    Operating Profit486501456644250
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes439438414637250
    Provision for Income Taxes
    Net Income After Taxes354356323563211
    Minority Interest
    Net Income Before Extraordinary Items
    Net Income358358326565214
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income358358326565214
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS0.2010.2170.2170.2090.162
    Dividends per Share
    Special Dividends per Share